Sex-dependent influence of endogenous estrogen in pulmonary hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 190, Issue 4, 2014, Pages 456-467

  Mair, Kirsty M ^a   Wright, Audrey F ^a   Duggan, Nicholas ^b   Rowlands, David J ^b   Hussey, Martin J ^b   Roberts, Sonia ^b   Fullerton, Josephine ^a   Nilsen, Margaret ^a   Loughlin, Lynn ^a   Thomas, Matthew ^b   MacLean, Margaret R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Estrogen; Pulmonary hypertension; Sex

Indexed keywords

ANASTROZOLE; AROMATASE; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; ESTROGEN; INHIBITOR OF DIFFERENTIATION 1; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART HEMODYNAMICS; HEART OUTPUT; HEART RATE; HEART RIGHT VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HYPOXIA; IMMUNOBLOTTING; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; RAT; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE; ANIMAL; ANOXIA; BLOOD; C57BL MOUSE; DISEASE MODEL; HUMAN; LUNG; METABOLISM; METHODOLOGY; POLYMERASE CHAIN REACTION; SEX DIFFERENCE; WESTERN BLOTTING; WISTAR RAT;

ESTROGEN; PULMONARY HYPERTENSION; SEX;

ANIMALS; ANOXIA; AROMATASE INHIBITORS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGENS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; MICE; MICE, INBRED C57BL; NITRILES; POLYMERASE CHAIN REACTION; RATS; RATS, WISTAR; SEX FACTORS; TRIAZOLES;

EID: 84907842509     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201403-0483OC     Document Type: Article

References (34)

1. Shapiro S, Traiger GL, Turner M, McGoon MD, Wason P, Barst RJ. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Chest 2012;141:363-373.
2. McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, Pepke-Zaba J, Pulido T, Rich S, Rosenkranz S, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013;62(Suppl. 25):D51-D59.
3. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2012;122:4306-4313.
4. Lahm T, Albrecht M, Fisher AJ, Selej M, Patel NG, Brown JA, Justice MJ, Brown MB, Van Demark M, Trulock KM, et al. 17b-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects. Am J Respir Crit Care Med 2012;185:965-980.
5. Umar S, Iorga A, Matori H, Nadadur RD, Li J, Maltese F, van der Laarse A, Eghbali M. Estrogen rescues preexisting severe pulmonary hypertension in rats. Am J Respir Crit Care Med 2011;184:715-723.
6. Xu DQ, Luo Y, Liu Y, Wang J, Zhang B, Xu M, Wang YX, Dong HY, Dong MQ, Zhao PT, et al. Beta-estradiol attenuates hypoxic pulmonary hypertension by stabilizing the expression of p27kip1 in rats. Respir Res 2010;11:182.
7. White K, Dempsie Y, Nilsen M, Wright AF, Loughlin L, MacLean MR. The serotonin transporter, gender, and 17β oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res 2011;90:373-382.
8. Dempsie Y, Nilsen M, White K, Mair KM, Loughlin L, Ambartsumian N, Rabinovitch M, MacLean MR. Development of pulmonary arterial hypertension in mice over-expressing s100a4/mts1 is specific to females. Respir Res 2011;12.
9. Dempsie Y, MacRitchie NA, White K, Morecroft I, Wright AF, Nilsen M, Loughlin L, Mair KM, MacLean MR. Dexfenfl uramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension. Cardiovasc Res 2013;99:24-34.
10. White K, Johansen AK, Nilsen M, Ciuclan L, Wallace E, Paton L, Campbell A, Morecroft I, Loughlin L, McClure JD, et al. Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. Circulation 2012;126:1087-1098.
11. Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, Speed C, Jones M. Aromatase - a brief overview. Annu Rev Physiol 2002; 64:93-127.
12. Dempsie Y, Morecroft I, Welsh DJ, MacRitchie NA, Herold N, Loughlin L, Nilsen M, Peacock AJ, Harmar A, Bader M, et al. Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation 2008;117:2928-2937.
13. Ciuclan L, Bonneau O, Hussey M, Duggan N, Holmes AM, Good R, Stringer R, Jones P, Morrell NW, Jarai G, et al. A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2011;184:1171-1182.
14. Keegan A, Morecroft I, Smillie D, Hicks MN, MacLean MR. Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935. Circ Res 2001;89:1231-1239.
15. Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I, Tighiouart H, Knowles JA, Rabinowitz D, Benza RL, et al.; Pulmonary Vascular Complications of Liver Disease Study Group. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med 2009;179:835-842.
16. Tofovic SP, Jackson EK. Complexities of oestradiol pharmacology in pulmonary arterial hypertension. Eur Respir J 2013;41:1465-1466.
17. Dukes M, Edwards PN, Large M, Smith IK, Boyle T. The preclinical pharmacology of "Arimidex" (anastrozole; ZD1033) - a potent, selective aromatase inhibitor. J Steroid Biochem Mol Biol 1996;58: 439-445.
18. Barrett-Connor E. Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys lecture. Circulation 1997;95:252-264.
19. Silber DH. Heart failure in women. Curr Womens Health Rep 2003;3:104-109.
20. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, Jessup M, Grizzle WE, Aldred MA, Cool CD, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:261-272.
21. Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 2007;18(Suppl 8):26-35.
22. Labrie F, Luu-The V, Lin SX, Labrie C, Simard J, Breton R, Bélanger A. The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology. Steroids 1997;62:148-158.
23. Yang J, Davies RJ, Southwood M, Long L, Yang X, Sobolewski A, Upton PD, Trembath RC, Morrell NW. Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension. Circ Res 2008;102:1212-1221.
24. Takahashi H, Goto N, Kojima Y, Tsuda Y, Morio Y, Muramatsu M, Fukuchi Y. Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006;290:L450-L458.
25. Long L, Crosby A, Yang X, Southwood M, Upton PD, Kim DK, Morrell NW. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 2009;119:566-576.
26. de Jesus Perez VA, Yuan K, Lyuksyutova MA, Dewey F, Orcholski ME, Shuffle EM, Mathur M, Yancy L Jr, Rojas V, Li CG, et al. Whole exome sequencing reveals TOPBP1 as a novel gene in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2014;189:1260-1272.
27. Girerd B, Perros F, Antigny F, Humbert M, Montani D. KCNK3: new gene target for pulmonary hypertension? Expert Rev Respir Med (In press)
28. Popovic RM, White DP. Upper airway muscle activity in normal women: influence of hormonal status. J Appl Physiol (1985) 1998;84:1055-1062.
29. Muxfeldt ES, Margallo VS, Guimarães GM, Salles GF. Prevalence and associated factors of obstructive sleep apnea in patients with resistant hypertension. Am J Hypertens (In press)
30. Presanis AM, Gill ON, Chadborn TR, Hill C, Hope V, Logan L, Rice BD, Delpech VC, Ades AE, De Angelis D. Insights into the rise in HIV infections, 2001 to 2008: a Bayesian synthesis of prevalence evidence. AIDS 2010;24:2849-2858.
31. Teichmann J, Schmidt A, Lange U, Stracke H, Discher T, Friese G, Lohmeyer J, Bretzel RG. Longitudinal evaluation of serum estradiol and estrone in male patients infected with the human immunodeficiency virus. Eur J Med Res 2003;8:77-80.
32. Schneider G, Kirschner MA, Berkowitz R, Ertel NH. Increased estrogen production in obese men. J Clin Endocrinol Metab 1979;48:633-638.
33. Zumoff B, Strain GW, Kream J, O'Connor J, Levin J, Fukushima DK. Obese young men have elevated plasma estrogen levels but obese premenopausal women do not. Metabolism 1981;30:1011-1014.
34. Plu-Bureau G, Hugon-Rodin J, Maitrot-Mantelet L, Canonico M. Hormonal contraceptives and arterial disease: an epidemiological update. Best Pract Res Clin Endocrinol Metab 2013;27:35-45.